Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2023-04-25 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于2022年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2022 annual profit distribution plan of the company. It details the proposed dividend payout, legal compliance, and approval process, including board and independent director opinions. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it focuses on the dividend distribution proposal and related approvals, which aligns with a Notice of Dividend Amount (DIV) filing. The document length is 2333 characters, which is consistent with a detailed dividend announcement rather than a full report.
2023-04-25 Chinese
关于补选第四届监事会非职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a supervisory board chairman and the nomination of a new non-employee representative supervisor. It includes details about the resignation, the legal basis for the replacement, and the nominee's biography. There are no financial statements, earnings data, or detailed management discussion. The document is a formal announcement about changes in the company's supervisory board members, which fits the category of Board/Management Information (MANG). The document length is short and focused on personnel changes, not a report or financial disclosure.
2023-04-25 Chinese
2022年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2022 年度董事会工作报告" which translates to "2022 Annual Board of Directors Work Report." It contains a detailed review of the company's operations, R&D, market activities, production, quality management, human resources, and plans for 2023. The content is comprehensive and covers the board's activities and company performance over the year. It is not a financial statement or earnings release but a detailed report on the board's work and company management. This fits the category of Board/Management Information (MANG), which includes announcements or reports about the company's board activities and management. The document length (9,341 characters) and detailed content confirm it is a full report, not a brief announcement or certification. Therefore, the appropriate classification is MANG with high confidence.
2023-04-25 Chinese
关于2023年度为全资子公司担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the expected guarantee amount for its wholly-owned subsidiaries in 2023. It details the board meeting resolutions, guarantee amounts, financial data of subsidiaries, and independent directors' opinions. The document is a formal disclosure about financing guarantees and does not contain full financial statements or comprehensive financial performance data. It is not an annual or interim report, nor an earnings release. It is also not a certification or a simple report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantee commitments for subsidiaries.
2023-04-25 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Meikang Biotechnology Co., Ltd. It details the approval of various reports and proposals related to the 2022 fiscal year, including the 2022 Annual Report, financial statements, profit distribution plan, internal control self-evaluation report, and other related matters. The document repeatedly states that the detailed contents of these reports are published separately on the designated disclosure website of the China Securities Regulatory Commission's ChiNext board. The document itself does not contain the full annual report or financial statements but rather the resolutions approving them and notes that these reports will be submitted to the 2022 Annual General Meeting for approval. The document length is 3694 characters, which is relatively short and mainly serves as an announcement of the Supervisory Board's meeting resolutions and approvals. Therefore, this document is not the Annual Report (10-K) itself but an announcement of meeting resolutions related to the annual report and other related documents. This fits best with the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories and includes meeting resolutions and announcements referencing other reports without containing the reports themselves.
2023-04-25 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 年年度报告摘要" which translates to "2022 Annual Report Summary". It contains detailed financial data for the year 2022, including revenue, net profit, assets, and shareholder information. It also includes audit opinions from the accounting firm, business overview, major accounting data, shareholder structure, and important company events during the year. The length of the document (7869 characters) and the detailed financial and operational data indicate this is a substantive financial report rather than a brief announcement or summary notice. The presence of audited financial statements and comprehensive business descriptions aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-04-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.